Key result
3-oxopyridazin-5-yl-chalcone hybrids exhibited antiplatelet activity substantially superior to clinical drugs and MNS by preventing GPIIb/IIIa activation.
Why the study?
Do 3-oxopyridazin-5-yl-chalcone hybrids exhibit potent antiplatelet activity by preventing GPIIb/IIIa activation compared to classical antagonists?
Do 3-oxopyridazin-5-yl-chalcone hybrids exhibit potent antiplatelet activity by preventing GPIIb/IIIa activation compared to classical antagonists?
Novel 3-oxopyridazin-5-yl-chalcone hybrids demonstrate potent antiplatelet activity by preventing GPIIb/IIIa activation, offering a potential new mechanism for treating platelet-dependent thrombosis.
Hypothesis-generating for novel antiplatelet agents; human trials needed before clinical consideration.
A novel family of potent and broad‐spectrum antiplatelet agents has been discovered by exploration of a library of 3‐oxopyridazin‐5‐yl‐chalcone hybrids. The pharmacological evaluation of the collection established the most salient features of the SAR in this series and allowed the identification of lead compounds that exhibit antiplatelet activity that is substantially superior to drugs in clinical use and 3,4‐methylenedioxy‐β‐nitrostyrene (MNS). The derivatives reported herein act on GPIIb/IIIa, but in a different manner to classical antagonists (e. g., tirofiban), by preventing GPIIb/IIIa activation. Given their mechanism of action, these compounds might avoid the adverse effects of antagonists (paradoxical GPIIb/IIIa activation) and constitute attractive pharmacological tools for the development of tailored agents for the treatment of platelet‐dependent thrombosis.
No takes yet. Share an insight, caveat, or question.
Maatougui et al. (2017) studied Platelet-dependent thrombosis. 3-oxopyridazin-5-yl-chalcone hybrids vs. Drugs in clinical use and 3,4-methylenedioxy-β-nitrostyrene (MNS) was evaluated on Antiplatelet activity and prevention of GPIIb/IIIa activation. 3-oxopyridazin-5-yl-chalcone hybrids exhibited antiplatelet activity substantially superior to clinical drugs and MNS by preventing GPIIb/IIIa activation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: